ClinicalTrials.gov
public full text
Public Domain
Paricalcitol in Fabry Disease
Proteinuria is the predominant risk factor for renal disease progression in Fabry disease (FD). When urine protein excretion is controlled to \0.50 g/24 hr persisting despite the ERT and anti-RAS therapy titrated to maximum tolerated dosage.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease Study#1140819
- Albuminuria Reduction With Renin Angiotensin System Inhibitors in SCA Patients#845417
- Podocyturia - Predictor of Renal Dysfunction in Fabry Nephropathy#1046403
- Proteinuria and chelator-associated renal dysfunction in β-thalassemia major: insights from a single-center clinical study#435557
- Supplementary Material for: Urinary Glucose Concentration as a Predictor of Proteinuria Reduction in CKD Patients Treated with SGLT2 Inhibitors#363843
Record · ID 978829
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive